These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Merck expanded access program August 11, 1995 deadline.
    Journal: Treat Rev; 1995; (no 19):3. PubMed ID: 11362754.
    Abstract:
    People with fewer than 50 T4 cells may register before August 11, 1995 to be considered for Crixivan, a protease inhibitor made by Merck. The registration number is 1-800-497-8383. Due to limited drug supply, a lottery will be necessary if more than 1,100 people apply. Potential participants must be at least 18 years of age; are permitted to have taken/be taking 3TC, d4T, ddI, ddC or AZT; must have more than 50,000 platelets; may not have acute hepatitis; and may not be pregnant. Those not selected via lottery will be placed on a waiting list.
    [Abstract] [Full Text] [Related] [New Search]